Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of alisertib when combined with
fractionated stereotactic radiosurgery in treating patients with high-grade gliomas that have
returned after previous treatment with radiation therapy (recurrent). Alisertib may stop the
growth of tumor cells by blocking an enzyme needed for the cells to divide. Radiation therapy
uses high energy x rays to kill tumor cells. Stereotactic radiosurgery uses special
positioning equipment to send a single high dose of radiation directly to the tumor and cause
less damage to normal tissue. Delivering stereotactic radiosurgery over multiple doses
(fractionation) may cause more damage to tumor tissue than normal tissue while maintaining
the advantage of its accuracy.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University